Lynx Therapeutics Overview

  • Founded
  • 1992

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 7

  • Investments
  • 3

Lynx Therapeutics General Information

Description

Developer of genetic analysis technologies for pharmaceutical, biotechnology and agricultural industries. The company's cloning and sequencing technologies provide comprehensive and quantitative digital gene expression data which is important to systems biology research enabling drug discovery and development companies to research, develop and implement new treatments for improving human health.

Contact Information

Website
www.lynxgen.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 25861 Industrial Boulevard
  • Hayward, CA 94545
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lynx Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lynx Therapeutics‘s full profile, request access.

Request a free trial

Lynx Therapeutics Patents

Lynx Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2003243720-A1 Method for detecting foreign dna in a host genome Inactive 21-Jun-2002 00000000000
US-20040086912-A1 Using fluorescent activated cell sorting to identify cells comprising heterologous nucleotide sequences; disease resistant plants; tissue engineering Inactive 21-Jun-2002 00000000000 0
US-20030206832-A1 Includes a patterned seal having a specified arrangement of holes and groves, and an connection plate having passages corresponding to the holes in the seal. Inactive 02-May-2002 000000000000
US-20030170700-A1 Modulating phenotypes; genetic engineering; adjust cholesterol concentration in blood Inactive 09-Jan-2002 000000000 00
US-20030180764-A1 A set of polynucleotide sequences that are differentially regulated in response to cholesterol and adipogenesis Inactive 09-Jan-2002 G01N33/92
To view Lynx Therapeutics’s complete patent history, request access »

Lynx Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Kevin Corcoran Board Member, President & Chief Executive Officer
To view Lynx Therapeutics’s complete executive team members history, request access »

Lynx Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lynx Therapeutics‘s full profile, request access.

Request a free trial

Lynx Therapeutics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 07-Mar-2005 0000000 00 Biotechnology
000000 000000 11-Dec-2001 000000000 000.00 Drug Discovery
Axaron Bioscience 23-Oct-1996 Joint Venture Drug Discovery
To view Lynx Therapeutics’s complete investments and acquisitions history, request access »

Lynx Therapeutics Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 0000000000 11-Dec-2001 000000000 000.00 Completed
  • 2 buyers
Axaron Bioscience 23-Oct-1996 Joint Venture Completed
  • 2 buyers
To view Lynx Therapeutics’s complete exits history, request access »